Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to other viruses, Epstein-Barr virus and its vector derivatives are very proficient reaching high infection and transduction rates in resting primary B cells [15].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nimmerjahn, F., Milosevic, S., Behrends, U., Jaffee, E. M., Pardoll, D. M., Bornkamm, G. W., & Mautner, J. (2003) · European Journal of Immunology · doi:10.1002/eji.200323730 · Cited by 359
Self-citation
Research works printed but not linked: 60
- Pardoll DM . Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227–238. · DOI · Paper page
- Kay MA, Glorioso JC, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33–40. · DOI · Paper page
- Rieger R, Kipps TJ . CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res 2003; 63: 4128–4135.
- Kofler DM, Buning H, Mayr C, Bund D, Baumert J, Hallek M et al. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2004; 11: 1416–1424. · DOI
- Hammerschmidt W, Sugden B . Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes. Nature 1989; 340: 393–397. · DOI · Paper page
- Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W . Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein–Barr virus. Cancer Res 2003; 63: 2982–2989.
- Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W et al. The Epstein–Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000; 19: 3080–3089. · DOI · Paper page
- Schepers A, Pich D, Hammerschmidt W . A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein–Barr virus. Eur Mol Biol Org J 1993; 12: 3921–3929. · doi:10.1002/j.1460-2075.1993.tb06070.x
- Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W . Propagation and recovery of intact, infectious Epstein–Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 1998; 95: 8245–8250. · DOI · Paper page
- Metcalf D, Burgess AW, Johnson GR, Nicola NA, Nice EC, DeLamarter J et al. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF. J Cell Physiol 1986; 128: 421–431. · DOI
- Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543. · DOI · Paper page
- Banchereau J, Steinman RM . Dendritic cells and the control of immunity. Nature 1998; 392: 245–252. · DOI · Paper page
- Dranoff G . GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188–3192. · DOI · Paper page
- Simons JW . Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer. Hinyokika Kiyo 1997; 43: 821–822.
- Dranoff G, Soiffer R, Lynch T, Mihm M, Jung K, Kolesar K et al. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 1997; 8: 111–123. · DOI
- Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21: 3343–3350. · DOI · Paper page
- Mahvi DM, Sondel PM, Yang NS, Albertini MR, Schiller JH, Hank J et al. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 1997; 8: 875–891. · doi:10.1089/hum.1997.8.7-875
- Nemunaitis J, Sterman D, Jablons D, Smith II JW, Fox B, Maples P et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Nat Cancer Inst 2004; 96: 326–331. · DOI · Paper page
- Delecluse HJ, Pich D, Hilsendegen T, Baum C, Hammerschmidt W . A first-generation packaging cell line for Epstein–Barr virus-derived vectors. Proc Natl Acad Sci USA 1999; 96: 5188–5193. · DOI
- Delecluse HJ, Hammerschmidt W . The genetic approach to the Epstein–Barr virus: from basic virology to gene therapy. Mol Pathol 2000; 53: 270–279. · doi:10.1136/mp.53.5.270
- Kieff E, Rickinson AB . Epstein–Barr virus and its replication. In: Knipe DM et al. (eds.), Field's Virology. Philadelphia: Lippincott-Williams & Wilkins, 2001, pp. 2511–2573.
- Kilger E, Kieser A, Baumann M, Hammerschmidt W . Epstein–Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998; 17: 1700–1709. · DOI · Paper page
- Dirmeier U, Hoffmann R, Kilger E, Schultheiss U, Briseño C, Gires O et al. Latent membrane protein 1 of Epstein–Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005; 24: 1711–1717. · DOI
- Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N . Expression of the Epstein–Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998; 95: 11963–11968. · DOI · Paper page
- Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ . Expression of the BNLF-1 oncogene of Epstein–Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990; 61: 1315–1327. · DOI
- Wang D, Liebowitz D, Kieff E . An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831–840. · DOI · Paper page
- Cohen JI, Wang F, Mannick J, Kieff E . Epstein–Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989; 86: 9558–9562. · DOI · Paper page
- Karasuyama H, Kudo A, Melchers F . The proteins encoded by the VpreB and lambda 5 pre-B cell-specific genes can associate with each other and with mu heavy chain. J Exp Med 1990; 172: 969–972. · DOI · Paper page
- Neuhierl B, Feederle R, Delecluse HJ . Glycoprotein gp110 of Epstein–Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci USA 2002; 99: 15036–15041. · DOI
- Sugden B, Mark W . Clonal transformation of adult human leukocytes by Epstein–Barr virus. J Virol 1977; 23: 503–508. · DOI · Paper page
- Klausner RD, Donaldson JG, Lippincott-Schwartz J . Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 1992; 116: 1071–1080. · DOI · Paper page
- Takada K, Horinouchi K, Ono Y, Aya T, Osato T, Takahashi M et al. An Epstein–Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 1991; 5: 147–156. · DOI · Paper page
- Goldblum N, Daefler S, Llana T, Ablashi D, Josephs S, Salahuddin Z . Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein–Barr virus. Dev Biol Stand 1990; 72: 309–313.
- Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989; 140: 323–334. · DOI · Paper page
- Nimmerjahn F, Kobelt D, Steinkasserer A, Menke A, Hobom G, Behrends U et al. Efficient generation and expansion of antigen-specific CD4+ T cells by recombinant influenza viruses. Eur J Immunol 2003; 33: 3331–3341. · DOI
- Sallusto F, Cella M, Danieli C, Lanzavecchia A . Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389–400. · DOI · Paper page
- Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497. · DOI · Paper page
- Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–419. · DOI · Paper page
- Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148–158. · DOI · Paper page
- Kreppel F, Kochanek S . Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol 2004; 78: 9–22. · DOI
- Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M . The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma 2004; 45: 897–904. · DOI
- Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ . CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917–2924. · DOI · Paper page
- Janssens W, Chuah MK, Naldini L, Follenzi A, Collen D, Saint-Remy JM et al. Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene Therapy 2003; 14: 263–276. · DOI
- Bonamino M, Serafini M, D'Amico G, Gaipa G, Todisco E, Bernasconi S et al. Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. Gene Therapy 2004; 11: 85–93. · DOI
- Lizee G, Gonzales MI, Topalian SL . Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum Gene Therapy 2004; 15: 393–404. · DOI
- Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M et al. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein–Barr virus. J Virol 1999; 73: 4678–4688. · DOI
- Conese M, Auriche C, Ascenzioni F . Gene therapy progress and prospects: episomally maintained self-replicating systems. Gene Therapy 2004; 11: 1735–1741. · DOI
- Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141–13146. · DOI · Paper page
- Strehl J, Selmayr M, Kremer JP, Hultner L, Lindhofer H, Mocikat R . Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells. Int J Cancer 1999; 83: 113–120. · doi:10.1002/(sici)1097-0215(19990924)83:1<113::aid-ijc20>3.0.co;2-j
- Selmayr M et al. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Therapy 1999; 6: 778–784. · DOI
- Mach N, Dranoff G . Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12: 571–575. · DOI
- Levitsky HI et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858–3865. · DOI · Paper page
- Maeda A et al. Epstein–Barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. J Hum Virol 2001; 4: 227–237.
- Teramoto N et al. Epstein–Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. J Hum Virol 2000; 3: 125–136.
- Wahl U et al. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation. Clin Cancer Res 2003; 9: 4240–4246.
- Posfai G, Koob MD, Kirkpatrick HA, Blattner FR . Versatile insertion plasmids for targeted genome manipulations in bacteria: isolation, deletion, and rescue of the pathogenicity island LEE of the Escherichia coli O157:H7 genome. J Bacteriol 1997; 179: 4426–4428. · DOI · Paper page
- O'Connor M, Peifer M, Bender W . Construction of large DNA segments in Escherichia coli. Science 1989; 244: 1307–1312. · DOI · Paper page
- Cherepanov PP, Wackernagel W . Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 1995; 158: 9–14. · DOI · Paper page
- Hammerschmidt W, Sugden B . Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein–Barr virus. Cell 1988; 55: 427–433. · DOI · Paper page
- Schultheiss U et al. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J 2001; 20: 5678–5691. · DOI
Cited by
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
(2013) · PubMed · Cited by 308
Akidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O. T., & Hammerschmidt, W. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009117 · Cited by 31
Self-citation
Metadata
- Authors
- Hellebrand, E., Mautner, J., Reisbach, G., Nimmerjahn, F., Hallek, M., Mocikat, R., & Hammerschmidt, W.
- Venue
- Gene Therapy
- Published
- 2005-09-01
- Volume
- 13
- Issue
- 2
- Pages
- 150-162
- ISSN
- 0969-7128
- 1476-5462
- Cited by
- 18
- References
- 1
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. https://app.cochat.ai/papers/10.1038/sj.gt.3302602
- The paper
- Hellebrand, E., Mautner, J., Reisbach, G., Nimmerjahn, F., Hallek, M., Mocikat, R., & Hammerschmidt, W. (2006). Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Gene Therapy. https://doi.org/10.1038/sj.gt.3302602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.